A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene
Doctors at the University of California, Los Angeles seek patients with severe Leukocyte Adhesion Deficiency-I (LAD-I) to trial a therapeutic gene therapy. This therapy utilizes the patient’s own (autologous) stem cells, which will be gene-modified in the lab to impart a gene for the CD18 immune cell receptor that is lacking in the LAD-I disease. They hope the gene will express the receptor after gene modification and improve the symptoms of the disease. Prior to the modified cells being re-administered via IV, the patient will receive chemotherapy.
Survival and improvement in the patients will be followed for 2 years.
- Be 3 months of age or older
- Have confirmed diagnosis of severe LAD-I meeting the study’s clinical criteria
- Not have a medically-eligible human leukocyte antigen (HLA)-identical sibling donor transplant.
THE STUDY INVOLVES:
- Screening to confirm acceptance to the study.
- Blood draw to recover the patient’s own stem cells, which will be gene-modified in the lab (no treatment during that period).
- Admission to the study center and a course of chemotherapy.
- Single infusion of gene-modified stem cells, with close observation, before the final dose of chemotherapy.
- Follow up will continue for 2 years.
LOCATIONS & CONTACTS:
The trial will take place at the University of California, Los Angeles. Map.
Donald B Kohn, MD | 310-794-1964 | [email protected]
Rocket Pharmaceuticals Inc.
Or go online: